Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A9 | P06702 | 6/20 | 0.62 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.41 |
| ▸ | CCR4 | P51679 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16235646 | 0.90 | S100A9 (0.57) | S100A9ACLYPTGES2CCR4ALDH1A1 | |
| SCHEMBL16235621 | 0.89 | S100A9 (0.49) | S100A9ACLYCCR4ALDH1A1HTT | |
| SCHEMBL16235689 | 0.88 | S100A9 (0.48) | S100A9ACLYPTGES2CCR4ALDH1A1 | |
| SCHEMBL16235520 | 0.84 | ALDH1A1 (0.52) | S100A9ALDH1A1HTTEP300KMT2A | |
| SCHEMBL16235475 | 0.84 | S100A9 (0.45) | S100A9ACLYPTGES2CCR4HTT | |
| SCHEMBL16235516 | 0.84 | S100A9 (0.44) | S100A9PTGES2CCR2 | |
| SCHEMBL16235240 | 0.82 | PTGES2 (0.46) | S100A9ACLYPTGES2ALDH1A1CCR2 | |
| SCHEMBL16234955 | 0.82 | KMT2A (0.52) | ACLYALDH1A1HTTKMT2A | |
| SCHEMBL16235976 | 0.81 | S100A9 (0.59) | S100A9PTGES2CCR4ALDH1A1 | |
| SCHEMBL16235277 | 0.81 | S100A9 (0.60) | S100A9PTGES2CCR4ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378763-A1 | COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM | CALPROTECT AB (SE) | 2022-12-01 | — | — | US | claimed |
| WO-2020260692-A1 | COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM | CALPROTECT AB (SE) | 2020-12-30 | — | — | WO | claimed |
| US-10125125-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-11-13 | — | — | US | claimed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | claimed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | claimed |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-04-28 | — | — | US | claimed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | claimed |
| EP-2925743-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | Active Biotech AB (SE) | 2015-10-07 | — | — | EP | claimed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | claimed |
| US-20220378763-A1 | COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM | CALPROTECT AB (SE) | 2022-12-01 | — | — | US | disclosed |
| WO-2020260692-A1 | COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM | CALPROTECT AB (SE) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020260692-A1 | COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM | CALPROTECT AB (SE) | 2020-12-30 | — | — | WO | disclosed |
| US-10125125-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-11-13 | — | — | US | disclosed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-04-28 | — | — | US | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2925743-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | Active Biotech AB (SE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378763-A1 | COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM | TNNT2, TNNI3, HMGB1 | S100A9 330/4885ACLY 1114/4885PTGES2 77/4885 |
| US-10125125-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | S100A9, S100B, S100A10 | S100A9 1/4885ACLY 4724/4885PTGES2 2209/4885 |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | S100A9 1/4885ACLY 4724/4885PTGES2 2209/4885 |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | S100A9 1/4885ACLY 4827/4885PTGES2 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.